Aerie Pharmaceuticals

Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Three companies on the “Horizon” with glaucoma drugsThe pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.
Rocket 2 meets safety endpoints for netarsudilNetarsudil ophthalmic solution 0.02% q.d. maintained consistent IOP-lowering efficacy through 12 months for the Rocket 2 trial.
A bullish view: Navigating beyond glaucoma company mistakesCompanies specializing in glaucoma products can make billions of dollars, but only if they can find a path through a minefield of scientific, regulatory, and marketing hazards, according to Richard A. Lewis, MD.
Rocket 2 results may tip the scaleAerie recently reported the results of its second phase III registration trial in the United States named Rocket 2, where the primary efficacy endpoint was to demonstrate non-inferiority of IOP lowering for Rhopressa compared with timolol.
ROCK inhibitors show promise in glaucoma treatmentA novel class of drugs ‒ rho-kinase, or ROCK inhibitors ‒ appears to lower IOP by relaxing the trabecular meshwork.
Fixed-dose combination glaucoma drug provides easy, safe IOP controlOnce-daily dosing of one drop of Roclatan (Aerie Pharmaceuticals, Inc.), containing a fixed-dose combination of latanoprost and a rho kinase inhibitor and norepinephrine transport inhibitor, was clinically and statistically superior to administration of its individual components for controlling IOP in open-angle glaucoma or ocular hypertension.
Directly targeting pathology: A novel approach to treating glaucomaRho kinase inhibitors are intriguing in that they work directly on the pathogenic mechanism of abnormally elevated IOP, increased resistance to trabecular outflow.
Latest glaucoma drugs with new MOA race to NDA submission
New glaucoma drugs aim to shake up marketReuters recently reported on a new wave of drugs in development that it says will shake up glaucoma treatments. When the consumer media is giving your patients direct information about eye care, are you ready to answer their questions?